Indications for Asciminib

Asciminib (Asciminib) is indicated for the treatment of adult patients with: Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML) chronic phase (CP) who has been previously treated with two or more tyrosine kinase inhibitors (TKIs); and T315I-mutated chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML). Ina phase 3 clinical trial, aximinib treatment had significantly higher rates of major molecular response and lower discontinuation rates compared with bosutinib. Several clinical trials are ongoing in different clinical settings to evaluate aceminib as first-line treatment for newly diagnosed CP-CML.